Dear Colleagues,

Neuroblastoma is the most common extracranial solid tumor in infants, with the highest incidence occurring within the first month of life. Despite extensive global efforts to improve outcomes for high-risk and progressive cases, long-term survival rates remain disheartening. This underscores the urgent need for a deeper understanding of the disease’s biology, its evolutionary trajectory, and the development of more effective therapeutic strategies.

This Special Issue aims to bring together original research, expert perspectives, and comprehensive reviews that explore the complex biology of high-risk and therapy-resistant neuroblastoma. We particularly welcome studies that investigate:

• Genetic, epigenetic, and immune landscapes of neuroblastoma
• Mechanisms of tumor evolution and cellular signaling pathways
• Genetic and molecular vulnerabilities induced by therapeutic pressure
• Novel targets and pathways for precision therapies
• Advances in molecularly targeted maintenance and salvage treatments

By compiling cutting-edge discoveries, emerging drug candidates, and innovative therapeutic approaches, this issue seeks to inform both the research and clinical communities. Our goal is to contribute to a paradigm shift in the treatment and potential cure of this devastating pediatric cancer.

Prof. Dr. Natarajan Aravindan
Guest Editor